ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,251Medicare Part D Prescriptions Filled, Including Refills

Rank: 696 out of 2343

$468K Total Retail Price of All Prescriptions

Rank: 745 out of 2343

249 Patients Receiving at Least One Drug in Part D
89%Patients 65 Years and Older
36% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Pennsylvania
Lower avg

Schedule Two
Controlled Substances

22% of this provider’s 249 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

6% of this provider’s 249 patients filled at least one prescription for a schedule three drug, compared to an average of 7%.

Risky Drugs to Seniors

1% of this provider’s 7,654 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$57 was the average price of a prescription from this provider, compared to $58 among peers.

Prescriptions per Patient

33 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Pennsylvania
METOPROLOL TARTRATE 408 398 1 7
METOPROLOL SUCCINATE 344 330 2 14
SIMVASTATIN 342 323 3 1
OMEPRAZOLE 306 271 4 4
ATORVASTATIN CALCIUM 301 298 5 10
FUROSEMIDE 291 282 6 6
LEVOTHYROXINE SODIUM 257 250 7 2
METFORMIN HCL 234 218 8 9
DILTIAZEM 24HR ER 172 167 9 76
LOSARTAN POTASSIUM 156 155 10 19
LOVASTATIN 146 114 11 47
DILTIAZEM 24HR CD 141 134 12 83
WARFARIN SODIUM 137 135 13 8
CLOPIDOGREL 134 127 14 26
ZETIA 132 120 15 52
OXYCODONE-ACETAMINOPHEN 125 104 S2 16 49
AMLODIPINE BESYLATE 120 108 17 5
CRESTOR 119 118 18 30
CARTIA XT 113 113 19 432
LISINOPRIL 103 92 20 3
MIRTAZAPINE 103 86 20 41
PANTOPRAZOLE SODIUM 96 96 22 22
ISOSORBIDE DINITRATE 95 86 23 354
SERTRALINE HCL 93 81 24 20
POTASSIUM CHLORIDE 91 91 25 18
ALENDRONATE SODIUM 88 88 26 28
PLAVIX 86 81 27 38
HYDROCHLOROTHIAZIDE 85 80 28 11
GLIMEPIRIDE 81 78 29 45
METFORMIN HCL ER 81 75 29 88
FENTANYL 67 57 S2 31 69
LIPITOR 64 64 32 78
PRAVASTATIN SODIUM 62 57 33 15
TRAZODONE HCL 60 52 34 53
DONEPEZIL HCL 59 59 35 21
KLOR-CON M20 57 54 36 44
HYDROCODONE-ACETAMINOPHEN 56 42 S3 37 13
CLOTRIMAZOLE-BETAMETHASONE 55 52 38 127
NEXIUM 53 40 39 33
RAMIPRIL 52 52 40 90
KLOR-CON M10 52 43 40 107
CEFUROXIME 52 46 40 193
DILTIAZEM ER 51 51 43 207
DIOVAN 51 39 43 23
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 14, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.